Jump to content

Uric acid

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by SiriusAlphaCMa (talk | contribs) at 09:47, 8 October 2012 (→Chemistry). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For the Romanian village of Uric, see Pui.
Uric acid
Kekulé, keletal formula of a minor uric acid tautomer
Kekulé, keletal formula of a minor uric acid tautomer
Spacefill model of a minor uric acid tautomer
Spacefill model of a minor uric acid tautomer

Crystals of uric acid in polarized light
Names
Preferred IUPAC name
7,9-Dihydro-1H-purine-2,6,8(3H)-trione[citation needed]
Other names
2,6,8-Trioxypurine[citation needed]
Identifiers
3D model (JSmol)
3DMet
156158
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.000.655 Edit this at Wikidata
EC Number
  • 200-720-7
KEGG
MeSH Uric+Acid
UNII
  • InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h5,12H,(H,9,10)(H,7,8,11) ☒N
    Key: DZGSAURIFGGOJK-UHFFFAOYSA-N ☒N
  • InChI=1/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)/f/h6-9H
    Key: LEHOTFFKMJEONL-UHFFFAOYAN
  • OC1Nc2nc(=O)nc2C(=O)N1
  • OC1NC2=NC(=O)N=C2C(=O)N1
Properties
C
5H
4N
4O
3
Molar mass 168.1103 g mol-1
Appearance White crystals
60 mg dm-3 (at 20 °C)
log P -1.107
Acidity (pKa) 5.6
Basicity (pKb) 8.4
Thermochemistry
166.15 J K-1 mol-1 (at 24.0 °C)
173.2 J K-1 mol-1
-619.69--617.93 kJ mol-1
-1.9212--1.91956 MJ mol-1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen, and hydrogen with the formula C5H4N4O3. It forms ions and salts known as urates and acid urates such as ammonium acid urate. Uric acid is a product of the metabolic breakdown of purine nucleotides. High blood concentrations of uric acid can lead to a type of arthritis known as gout. The chemical is associated with other medical conditions including diabetes and the formation of ammonium acid urate kidney stones.

Chemistry

Uric acid is a diprotic acid with pKa1=5.4 and pKa2=10.3.[1] Thus in strong alkali at high pH, it forms the dually charged full urate ion, but at biological pH or in the presence of carbonic acid or carbonate ions, it forms the singly charged hydrogen or acid urate ion as its pKa1 is lower than the pKa1 of carbonic acid. As its second ionization is so weak, the full urate salts tend to hydrolyze back to hydrogen urate salts and free base at pH values around neutral. It is aromatic because of the purine functional group.

As a bicyclic, heterocyclic purine derivative, uric acid does not protonate at an oxygen [-OH] like carboxylic acids do. X-Ray diffraction studies on the hydrogen urate ion in crystals of ammomium hydrogen urate, formed in vivo as gouty deposits, reveal the keto-oxygen in the 2 position of a tautomer of the purine structure exists as a hydroxyl group and the two flanking nitrogen atoms at the 1 and 3 positions share the ionic charge in the six membered pi-resonance-stabilized ring.[2]

Thus, while most organic acids are deprotonated by the ionization of a polar hydrogen-to-oxygen bond, usually accompanied by some form of resonance stabilization (resulting in a carboxylate ion), uric acid is deprotonated at a nitrogen atom and uses a tautomeric keto/hydroxy group as an electron-withdrawing group to increase the pK1 value. The five membered ring also possesses a keto group (in the 8 position), flanked by two secondary amino groups (in the 7 and 9 positions), and deprotonation of one of these at high pH could explain the pK2 and behavior as a diprotic acid. Similar tautomeric rearrangement and pi-resonance stabilization would then give the ion some degree of stability. (On the structure shown at the upper right, the NH at the upper right on the six membered ring is "1", counting clockwise around the six membered ring to "6" for the keto carbon at the top of the six membered ring. The upper most NH on the five membered ring is "7", counting counter clockwise around this ring to the lower NH, which is "9".)

Uric acid was first isolated from kidney stones in 1776 by Scheele.[3] As far as laboratory synthesis is concerned, in 1882, Horbaczewski claimed to have prepared uric acid by melting urea hydrogen peroxide with glycine, trichlorolactic acid, and its amide. Soon after, repetition by Eduard Hoffmann shows that this preparation with glycine gives no trace of uric acid, but trichlorolactimide produces some uric acid. Thus, Hoffmann was the first to synthesize uric acid.[4]

Solubility

Generally, the water solubilitity of uric acid and its alkali metal and alkaline earth salts is rather low. All these salts exhibit greater solubility in hot water than cold, allowing for easy recrystallization. This low solubility is significant for the etiology of gout. The solubility of the acid and its salts in ethanol is very low or negligible. In ethanol water mixtures, the solubilities are somewhere between the end values for pure ethanol and pure water.

Compound Cold Water Boiling Water
Uric Acid 15000 2000
NH4HUrate - 1600
LiHUrate 370 39
NaHUrate 1175 124
KHUrate 790 75
Mg(HUrate)2 3750 160
Ca(HUrate)2 603 276
Na2Urate 77 -
K2Urate 44 35
CaUrate 1500 1440
SrUrate 4300 1790
BaUrate 7900 2700

The figures given indicate what mass of water is required to dissolve a unit mass of compound indicated, the lower the number, the more soluble the substance in the said solvent.[5][6][7]

Biology

The enzyme xanthine oxidase makes uric acid from xanthine and hypoxanthine, which in turn are produced from other purines. Xanthine oxidase is a large enzyme whose active site consists of the metal, molybdenum, bound to sulfur and oxygen.[8] Within cells, xanthine oxidase can exist as xanthine dehydrogenase and xanthine oxireductase, which has also been purified from bovine milk and spleen extracts.[9] Uric acid is released in hypoxic conditions.[10]

In humans and higher primates, uric acid is the final oxidation (breakdown) product of purine metabolism and is excreted in urine. In most other mammals, the enzyme uricase further oxidizes uric acid to allantoin.[11] The loss of uricase in higher primates parallels the similar loss of the ability to synthesize ascorbic acid, leading to the suggestion that urate may partially substitute for ascorbate in such species.[12] Both uric acid and ascorbic acid are strong reducing agents (electron donors) and potent antioxidants. In humans, over half the antioxidant capacity of blood plasma comes from uric acid.[13] The Dalmatian dog has a genetic defect in uric acid uptake by the liver and kidneys, resulting in decreased conversion to allantoin, so this breed excretes uric acid, and not allantoin, in the urine.[14]

In birds and reptiles, and in some desert dwelling mammals (e.g., the kangaroo rat), uric acid also is the end product of purine metabolism, but it is excreted in feces as a dry mass. This involves a complex metabolic pathway that is energetically costly in comparison to processing of other nitrogenous wastes such as urea (from urea cycle) or ammonia, but has the advantage of reducing water loss.[15]

In humans, about 70% of daily uric acid disposal occurs via the kidneys, and in 5-25% of humans, impaired renal (kidney) excretion leads to hyperuricemia.[16]

Genetics

A proportion of people have mutations in the proteins responsible for the excretion of uric acid by the kidneys. Nine genes have so far been identified: SLC2A9; ABCG2; SLC17A1; SLC22A11; SLC22A12; SLC16A9; GCKR; LRRC16A; and PDZK1.[17][18] SLC2A9 is known to transport both uric acid and fructose.[16][19]

Medicine

In human blood plasma, the reference range of uric acid is between 3.6 mg/dL (~214 µmol/L) and 8.3 mg/dL (~494 µmol/L) (1 mg/dL=59.48 µmol/L),[20] and 2.3-6.6 mg/dL for woman (137-393 µmol/L). This range is considered normal by the American Medical Association Manual of Style.[21] Uric acid concentrations in blood plasma above and below the normal range are known, respectively, as hyperuricemia and hypouricemia. Similarly, uric acid concentrations in urine above and below normal are known as hyperuricosuria and hypouricosuria. Such abnormal concentrations of uric acid are not medical conditions, but are associated with a variety of medical conditions.[citation needed]

Reference ranges for blood tests, comparing blood content of uric acid (shown in yellow) with other constituents

High uric acid

High levels of uric acid is called hyperuricemia .

Causes of high uric acid

  • In many instances, people have elevated uric acid levels for hereditary reasons.
  • Diet may be a factor. High intake of dietary purine as well as fructose (and table sugar which is roughly 50% fructose) can cause increased levels of uric acid.[22]
  • Serum uric acid can be elevated due to reduced excretion by the kidneys.[23]
  • Fasting or rapid weight loss can temporarily elevate uric acid levels.
  • Iron (Fe) activates xanthine oxidase (XO) and copper (Cu) deactivates it, so as men accumulate Fe with age (ferritin levels rise above 45 ng/dl) and Cu levels decline as testosterone levels drop with age (testosterone increases Cu half life), eventually the high Fe/Cu results in more active XO and higher urate levels.[citation needed] Excess Fe can be eliminated through phlebotomy (blood donation) and low Cu can be corrected through daily intake of 2 mg Cu per day, reducing urate levels.[citation needed]

Gout

Excess serum accumulation of uric acid in the blood can lead to a type of arthritis known as gout.[24] This painful condition is the result of needle-like crystals of uric acid precipitating in joints, capillaries, skin, and other tissues. Kidney stones can also form through the process of formation and deposition of sodium urate microcrystals.[25][26]

A study found that men who drank two or more sugar-sweetened beverages a day have an 85% higher chance of developing gout than those who drank such beverages infrequently.[27]

Gout can occur where serum uric acid levels are as low as 6 mg/dL (~357 µmol/L), but an individual can have serum values as high as 9.6 mg/dL (~565 µmol/L) and not have gout.[28]

One treatment for gout, in the 19th century, had been administration of lithium salts;[29] lithium urate is more soluble. Today, inflammation during attacks is more commonly treated with NSAIDs or corticosteroids, and urate levels are managed with allopurinol.[30] Allopurinol, developed over 30 years ago by Elion et al., weakly inhibits xanthine oxidase. It is an analog of hypoxanthine that is hydroxylated by xanthine oxireductase at the 2-position to give oxipurinol. Oxipurinol has been supposed to bind tightly to the reduced molybdenum ion in the enzyme and thus inhibits uric acid synthesis.[31]

Lesch-Nyhan syndrome

Lesch-Nyhan syndrome, an extremely rare inherited disorder, is also associated with very high serum uric acid levels.[32] Spasticity, involuntary movement and cognitive retardation as well as manifestations of gout are seen in cases of this syndrome.[33]

Cardiovascular disease

Although uric acid can act as an antioxidant, excess serum accumulation is often associated with cardiovascular disease. It is not known whether this is causative (e.g., by acting as a prooxidant ) or a protective reaction taking advantage of urate's antioxidant properties.[24][34] The same may account for the putative role of uric acid in the etiology of stroke.[35]

Type 2 diabetes

The association of high serum uric acid with insulin resistance has been known since the early part of the 20th century, nevertheless, recognition of high serum uric acid as a risk factor for diabetes has been a matter of debate. In fact, hyperuricemia has always been presumed to be a consequence of insulin resistance rather than its precursor.[36] However, a prospective follow-up study showed high serum uric acid is associated with higher risk of type 2 diabetes, independent of obesity, dyslipidemia, and hypertension.[37]

Metabolic syndrome

Hyperuricemia is associated with components of metabolic syndrome. A study has suggested fructose-induced hyperuricemia may play a pathogenic role in the metabolic syndrome.[38] This is consistent with the increased consumption in recent decades of fructose-containing beverages (such as fruit juices and soft drinks sweetened with sugar and high-fructose corn syrup) and the epidemic of diabetes and obesity.[27]

Uric acid stone formation

Saturation levels of uric acid in blood may result in one form of kidney stones when the urate crystallizes in the kidney. These uric acid stones are radiolucent and so do not appear on an abdominal plain X-ray, and thus their presence must be diagnosed by ultrasound for this reason. Very large stones may be detected on X-ray by their displacement of the surrounding kidney tissues.

Uric acid stones, which form in the absence of secondary causes such as chronic diarrhea, vigorous exercise, dehydration, and animal protein loading, are felt to be secondary to obesity and insulin resistance seen in metabolic syndrome. Increased dietary acid leads to increased endogenous acid production in the liver and muscles, which in turn leads to an increased acid load to the kidneys. This load is handled more poorly because of renal fat infiltration and insulin resistance, which are felt to impair ammonia excretion (a buffer). The urine is therefore quite acidic, and uric acid becomes insoluble, crystallizes and stones form. In addition, naturally present promoter and inhibitor factors may be affected. This explains the high prevalence of uric stones and unusually acidic urine seen in patients with type 2 diabetes. Uric acid crystals can also promote the formation of calcium oxalate stones, acting as "seed crystals" (heterogeneous nucleation).[39]

Low uric acid

Causes of low uric acid

Low uric acid (hypouricemia) can have numerous causes.

Low dietary zinc intakes cause lower uric acid levels. This effect can be even more pronounced in women taking oral contraceptive medication.[40]

Xanthine oxidase is an Fe-Mo enzyme, so people with Fe deficiency (the most common cause of anemia in young women) or Mo deficiency can experience hypouricemia.

Xanthine oxidase loses its function and gains ascorbase function when some of the Fe atoms in XO are replaced with Cu atoms. Accordingly, people with high Cu/Fe can experience hypouricemia and vitamin C deficiency, resulting in oxidative damage. Since estrogen increases the half life of Cu, women with very high estrogen levels and intense blood loss during menstruation are likely to have a high Cu/Fe and present with hypouricemia.

Sevelamer, a drug indicated for prevention of hyperphosphataemia in patients with chronic renal failure, can significantly reduce serum uric acid.[41]

Multiple sclerosis

Lower serum values of uric acid have been associated with multiple sclerosis (MS). MS patients have been found to have serum levels ~194 µmol/L, with patients in relapse averaging ~160 µmol/L and patients in remission averaging ~230 µmol/L. Serum uric acid in healthy controls was ~290 µmol/L.[42] Conversion factor: 1 mg/dL=59.48 µmol/L[20]

A 1998 study completed a statistical analysis of 20 million patient records, comparing serum uric acid values in patients with gout and patients with multiple sclerosis. Almost no overlap between the groups was found.[43]

Uric acid has been successfully used in the treatment and prevention of the animal (murine) model of MS. A 2006 study found elevation of serum uric acid values in multiple sclerosis patients, by oral supplementation with inosine, resulted in lower relapse rates, and no adverse effects.[44]

Normalizing low uric acid

Correcting low or deficient zinc levels can help elevate serum uric acid.[45] Inosine can be used to elevate uric acid levels.[42] Zn inhibits Cu absorption, helping to reduce the high Cu/Fe in some people with hypouricemia. Fe supplements can ensure adequate Fe reserves (ferritin above 25 ng/dl), also correcting the high Cu/Fe.

Oxidative stress

Uric acid may be a marker of oxidative stress,[46] and may have a potential therapeutic role as an antioxidant.[47] On the other hand, like other strong reducing substances such as ascorbate, uric acid can also act as a prooxidant,[48] particularly at elevated levels. Thus, it is unclear whether elevated levels of uric acid in diseases associated with oxidative stress such as stroke and atherosclerosis are a protective response or a primary cause.[34][49]

For example, some researchers propose hyperuricemia-induced oxidative stress is a cause of metabolic syndrome.[38][50] On the other hand, plasma uric acid levels correlate with longevity in primates and other mammals.[51] This is presumably a function of urate's antioxidant properties.[52]

Sources

  • In humans, purines are excreted as uric acid. Purines are found in high amounts in animal food products, such as liver and sardines.[53] A moderate amount of purine is also contained in beef, pork, poultry, fish and seafood, asparagus, cauliflower, spinach, mushrooms, green peas, lentils, dried peas, beans, oatmeal, wheat bran and wheat germ.[54]
  • Moderate intake of purine-containing food is not associated with an increased risk of gout.[55]

References

  1. ^ McCrudden, Francis H. (2008). Uric Acid. BiblioBazaar.
  2. ^ European Powder Diffraction Conference, EPDIC-9
  3. ^ Scheele, V. Q. Examen Chemicum Calculi Urinari, Opuscula, 1776, 2, 73.
  4. ^ Behrend, R. History of the uric acid synthesis. Justus Liebigs Ann. Chem. 1925, 441, 215.
  5. ^ C.R.C. 62nd Ed.
  6. ^ MERK Index, Ninth Ed.
  7. ^ Uric Acid, Francis H. McCrudden, page 58
  8. ^ Hille, R. Molybdenum-containing hydroxylases. ARCH BIOCHEM BIOPHYS 2004, 433, 107-116.
  9. ^ Hori, N.; Uehara, K.; Mikami, Y. Enzymic synthesis of 5-methyluridine from adenosine and thymine with high efficiency. Biosci. , Biotechnol. , Biochem. 1992, 56, 580-582.
  10. ^ Baillie, J.K. (2007-05). "Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude". Chest. 131 (5): 1473–1478. doi:10.1378/chest.06-2235. PMID 17494796. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  11. ^ Angstadt, Carol N. (1997-12-04). Purine and Pyrimidine Metabolism: Purine Catabolism. NetBiochem, 4 December 1997. Retrieved from http://library.med.utah.edu/NetBiochem/pupyr/pp.htm#Pu%20Catab.
  12. ^ Proctor P (1970-11). "Similar functions of uric acid and ascorbate in man?". Nature. 228 (5274): 868. doi:10.1038/228868a0. PMID 5477017. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |month= ignored (help)
  13. ^ S. R. J. Maxwell, H. Thomason, D. Sandler, C. Leguen, M. A. Baxter, G. H. G. Thorpe, A. F. Jones, A. H. Barnett. "Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus" European Journal of Clinical Investigation (1997) 27, 484-490. Blackwell Science Ltd., retrieved from http://www3.interscience.wiley.com/journal/119145773/abstract
  14. ^ Friedman, Meyer; and Byers, Sanford O. (1 September 1948). "Observations concerning the causes of the excess excretion of uric acid in the Dalmatian dog". The Journal of Biological Chemistry. 175 (2): 727–35. PMID 18880769.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ Hazard, Lisa C. (2004). Sodium and Potassium Secretion by Iguana Salt Glands. University of California Press. pp. 84–85. ISBN 978-0-520-23854-1. {{cite book}}: |work= ignored (help)
  16. ^ a b Vitart V, Rudan I, Hayward C; et al. (2008-04). "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout". Nature Genetics. 40 (4): 437–42. doi:10.1038/ng.106. PMID 18327257. {{cite journal}}: Check date values in: |date= (help); Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  17. ^ Aringer M, Graessler J (2008). "Understanding deficient elimination of uric acid". Lancet. 372 (9654): 1929–30. doi:10.1016/S0140-6736(08)61344-6. PMID 18834627. {{cite journal}}: Unknown parameter |month= ignored (help)
  18. ^ Kolz M, Johnson T ; et al. (2009). Allison, David B. (ed.). "Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations". PLoS Genet. 5 (6): e1000504. doi:10.1371/journal.pgen.1000504. PMC 2683940. PMID 19503597. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)
  19. ^ Döring A, Gieger C, Mehta D; et al. (2008). "SLC2A9 influences uric acid concentrations with pronounced sex-specific effects". Nature Genetics. 40 (4): 430–6. doi:10.1038/ng.107. PMID 18327256. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  20. ^ a b SI Units for Clinical Data
  21. ^ AMA Manual of Style Web site. Units of measure conversion table. http://www.amamanualofstyle.com/oso/public/jama/si_conversion_table.html
  22. ^ Cirillo P, Sato W, Reungjui S; et al. (2006). "Uric acid, the metabolic syndrome, and renal disease". J. Am. Soc. Nephrol. 17 (12 Suppl 3): S165–8. doi:10.1681/ASN.2006080909. PMID 17130256. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  23. ^ Mayo Clinic staff. (September 11, 2010). High uric acid level. Mayo Clinic. Retrieved April 24, 2011.
  24. ^ a b Heinig M, Johnson RJ (2006). "Role of uric acid in hypertension, renal disease, and metabolic syndrome". Cleveland Clinic Journal of Medicine. 73 (12): 1059–64. doi:10.3949/ccjm.73.12.1059. PMID 17190309. {{cite journal}}: Unknown parameter |month= ignored (help)
  25. ^ Banach, K.; Bojarska, E.; Kazimierczuk, Z.; Magnowska, L.; Bzowska, A. Kinetic Model of Oxidation Catalyzed by Xanthine Oxidase—The Final Enzyme in Degradation of Purine Nucleosides and Nucleotides. Nucleosides Nucleotides Nucleic Acids 2005, 24, 465-469.
  26. ^ "What is Gout: What Causes Gout?". MedicalBug. 6 January 2012. Retrieved 6 May 2012.
  27. ^ a b Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB. (November 2010). Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 33 (11): 2477–2483. doi:10.2337/dc10-1079. PMID 20693348.
  28. ^ Tausche AK, Unger S, Richter K; et al. (2006). "Hyperurikämie und Gicht". Der Internist (in German). 47 (5): 509–20, quiz 521. doi:10.1007/s00108-006-1578-y. PMID 16586130. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help); Unknown parameter |trans_title= ignored (|trans-title= suggested) (help)CS1 maint: multiple names: authors list (link)
  29. ^ Gerhard N. Schrauzer (2002). "Lithium: Occurrence, Dietary Intakes, Nutritional Essentiality". Journal of the American College of Nutrition. 21 (1): 14–21. PMID 11838882.
  30. ^ NHS Clinical Knowledge Summaries http://www.cks.nhs.uk/gout/background_information/causes_and_risk_factors#-291124
  31. ^ Okamoto, K.; Eger, B. T.; Nishino, T.; Pai, E. F.; Nishino, T. Mechanism of Inhibition of Xanthine Oxidoreductase by Allopurinol: Crystal Structure of Reduced Bovine Milk Xanthine Oxidoreductase Bound with Oxipurinol. Nucleosides Nucleotides Nucleic Acids 2008, 27, 888-893.
  32. ^ Luo YC, Do JS, Liu CC (2006). "An amperometric uric acid biosensor based on modified Ir-C electrode". Biosensors & Bioelectronics. 22 (4): 482–8. doi:10.1016/j.bios.2006.07.013. PMID 16908130. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  33. ^ Nyhan WL (2005). "Lesch-Nyhan Disease". Journal of the History of the Neurosciences. 14 (1): 1–10. doi:10.1080/096470490512490. PMID 15804753. {{cite journal}}: Unknown parameter |month= ignored (help)
  34. ^ a b Proctor, Peter H. "Free Radicals and Human Disease". CRC Handbook of Free Radicals and Antioxidants. 1989. pp. 209–221. Retrieved 6 May 2012.
  35. ^ Uric Acid: Neuroprotective or Neurotoxic?
  36. ^ Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M (1993). "Uric acid metabolism and tubular sodium handling. Results from a population-based study". JAMA. 270 (3): 354–9. doi:10.1001/jama.270.3.354. PMID 8315780. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  37. ^ Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC (2008). "High serum uric acid as a novel risk factor for type 2 diabetes". Diabetes Care. 31 (2): 361–2. doi:10.2337/dc07-1276. PMID 17977935. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  38. ^ a b Nakagawa T, Hu H, Zharikov S; et al. (2006). "A causal role for uric acid in fructose-induced metabolic syndrome". American Journal of Physiology. Renal Physiology. 290 (3): F625–31. doi:10.1152/ajprenal.00140.2005. PMID 16234313. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  39. ^ Pak CY (2008). "Medical stone management: 35 years of advances". The Journal of Urology. 180 (3): 813–9. doi:10.1016/j.juro.2008.05.048. PMID 18635234. {{cite journal}}: Unknown parameter |month= ignored (help)
  40. ^ Hess FM, King JC, Margen S (1 December 1977). "Effect of low zinc intake and oral contraceptive agents on nitrogen utilization and clinical findings in young women". The Journal of Nutrition. 107 (12): 2219–27. PMID 925768.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ^ Garg JP, Chasan-Taber S, Blair A; et al. (2005). "Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial". Arthritis and Rheumatism. 52 (1): 290–5. doi:10.1002/art.20781. PMID 15641045. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  42. ^ a b Toncev G, Milicic B, Toncev S, Samardzic G (2002). "Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction". European Journal of Neurology. 9 (3): 221–6. doi:10.1046/j.1468-1331.2002.00384.x. PMID 11985629. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  43. ^ Hooper DC, Spitsin S, Kean RB; et al. (1998). "Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis". Proceedings of the National Academy of Sciences of the United States of America. 95 (2): 675–80. doi:10.1073/pnas.95.2.675. PMC 18479. PMID 9435251. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  44. ^ Toncev G (2006). "Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis". Vojnosanitetski Pregled. 63 (10): 879–82. doi:10.2298/VSP0610879T. PMID 17121380. {{cite journal}}: Unknown parameter |month= ignored (help)
  45. ^ Umeki S, Ohga R, Konishi Y, Yasuda T, Morimoto K, Terao A (1986). "Oral zinc therapy normalizes serum uric acid level in Wilson's disease patients". The American Journal of the Medical Sciences. 292 (5): 289–92. doi:10.1097/00000441-198611000-00007. PMID 3777013. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  46. ^ Becker BF (1993). "Towards the physiological function of uric acid". Free Radical Biology & Medicine. 14 (6): 615–31. doi:10.1016/0891-5849(93)90143-I. PMID 8325534. {{cite journal}}: Unknown parameter |month= ignored (help)
  47. ^ Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA (2005). "Uric acid and oxidative stress". Current Pharmaceutical Design. 11 (32): 4145–51. doi:10.2174/138161205774913255. PMID 16375736.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  48. ^ Proctor P (1972). "Electron-transfer factors in psychosis and dyskinesia". Physiological Chemistry and Physics. 4 (4): 349–60. PMID 4680784.
  49. ^ Proctor PH (2008). "Uric acid: neuroprotective or neurotoxic?". Stroke. 39 (5): e88, author reply e89. doi:10.1161/STROKEAHA.107.513242. PMID 18369163. {{cite journal}}: Unknown parameter |month= ignored (help)
  50. ^ Hayden MR, Tyagi SC (2004). "Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle". Nutrition & Metabolism. 1 (1): 10. doi:10.1186/1743-7075-1-10. PMC 529248. PMID 15507132.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  51. ^ Cutler RG (1984). "Urate and ascorbate: their possible roles as antioxidants in determining longevity of mammalian species". Archives of Gerontology and Geriatrics. 3 (4): 321–48. doi:10.1016/0167-4943(84)90033-5. PMID 6532339. {{cite journal}}: Unknown parameter |month= ignored (help)
  52. ^ Ames BN; et al. (1981). "Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis". Proc Natl Acad Sci U S A. 78 (11): 6858–62. doi:10.1073/pnas.78.11.6858. PMC 349151. PMID 6947260. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)
  53. ^ Gout Causes: List of Diet/Food Sources High or Low in Purine Content
  54. ^ Gout Diet / Low Purine Diet - Limit High Purine foods
  55. ^ Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004). "Purine-rich foods, dairy and protein intake, and the risk of gout in men". The New England Journal of Medicine. 350 (11): 1093–103. doi:10.1056/NEJMoa035700. PMID 15014182. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

Further reading

  • Nakamura, T. (April 2008). [Historical review of gout and hyperuricemia investigations]. Nippon Rinsho 66 (4): 624-635. PMID 18409506.
Wikimedia Commons has media related to Uric acid.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Uric_acid&oldid=516606231"